Scholar Rock Adjusts Regulatory Strategy for SMA Drug Apitegromab
Event summary
- Scholar Rock removed Catalent Indiana as a commercial fill-finish facility from its apitegromab BLA in the U.S., maintaining a September 30, 2026 PDUFA decision date.
- The company withdrew its apitegromab MAA in Europe and plans to resubmit with an alternate fill-finish facility.
- Scholar Rock is on track to submit a Japanese New Drug Application (JNDA) for apitegromab by year-end 2026 without requiring additional clinical studies in Japan.
The big picture
Scholar Rock's strategic pivot to an alternate fill-finish facility underscores the complexities of global regulatory approvals for rare disease treatments. The company's ability to navigate these challenges will be critical as it aims to bring apitegromab to patients in the U.S., Europe, and Japan. The shift highlights the importance of regulatory flexibility and supply chain resilience in the biopharmaceutical industry.
What we're watching
- Regulatory Approval Timing
- Whether the FDA will approve apitegromab by the September 30, 2026 PDUFA date despite the change in fill-finish facilities.
- Market Access Strategy
- How quickly Scholar Rock can resubmit and gain approval for apitegromab in Europe after removing Catalent Indiana from the MAA.
- Commercial Readiness
- The pace at which Scholar Rock can scale commercial production and distribution of apitegromab following regulatory approvals.